Clinical trial
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor…
NCT00050323 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00050323 |
|---|---|
| Title | Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer |
| Official title | Phase 1/2 Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusion in Patients With AJCC Stage IV Renal Cell Carcinoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Allogeneic DCs and Autologous RCC Tumor Derived Cells |
| Enrollment | 30 |
| Start date | Nov 1, 2002 |
| Completion | Mar 1, 2004 |
| First posted | Dec 5, 2002 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: